Argus Research
- Home
- CNMD
CNMD
CONMED Corporation
as of 03-06-2026 3:55pm EST
$40.10
$1.30
-3.14%
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | LARGO |
| Market Cap: | 1.3B | IPO Year: | 1995 |
| Target Price: | $51.20 | AVG Volume (30 days): | 447.6K |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 1.51 | EPS Growth: | -64.47 |
| 52 Week Low/High: | $35.37 - $64.87 | Next Earning Date: | 04-27-2026 |
| Revenue: | $1,374,724,000 | Revenue Growth: | 5.18% |
| Revenue Growth (this year): | 0.82% | Revenue Growth (next year): | 5.48% |
| P/E Ratio: | 27.57 | Index: | N/A |
| Free Cash Flow: | 150.9M | FCF Growth: | -1.95% |
AI-Powered CNMD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.01%
73.01%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 28, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 28, 2026 · 100% conf.
AI Prediction BUY
1D
+4.17%
$40.30
5D
+7.66%
$41.65
20D
+9.02%
$42.18
Price: $38.69 Prob +5D: 100% AUC: 1.000
0000816956-26-000006
cnmd-20260128FALSE000081695600008169562026-01-282026-01-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 28, 2026
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-3921816-0977505 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
11311 Concept Blvd Largo, FL 33773 (Address of principal executive offices)(Zip code)
(727) 392-6464 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of the Act
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par valueCNMDNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition
On January 28, 2026, CONMED Corporation issued a press release announcing financial results for the fourth quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are included herewith:
Exhibit No.Description of Exhibit 99.1Press release dated January 28, 2026, issued by CONMED Corporation.
104Cover Page Interactive Data File (embedded within the Inline XBRL Document).
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 28, 2026
CONMED CORPORATION
(Registrant)
By: /s/ Todd W. Garner Name:Todd W. Garner Title:Executive Vice President, Finance & Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0000816956-25-000054
cnmd-20251105FALSE000081695600008169562025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 5, 2025
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-3921816-0977505 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
11311 Concept Blvd Largo, FL 33773 (Address of principal executive offices)(Zip code)
(727) 392-6464 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of the Act
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par valueCNMDNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition
On November 5, 2025, CONMED Corporation issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are included herewith:
Exhibit No.Description of Exhibit 99.1Press release dated November 5, 2025, issued by CONMED Corporation.
104Cover Page Interactive Data File (embedded within the Inline XBRL Document).
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2025
CONMED CORPORATION
(Registrant)
By: /s/ Todd W. Garner Name:Todd W. Garner Title:Executive Vice President, Finance & Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 30, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 30, 2025
0000816956-25-000026
cnmd-20250730FALSE000081695600008169562025-07-302025-07-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 30, 2025
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-3921816-0977505 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
11311 Concept Blvd Largo, FL 33773 (Address of principal executive offices)(Zip code)
(727) 392-6464 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of the Act
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par valueCNMDNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition
On July 30, 2025, CONMED Corporation issued a press release announcing financial results for the second quarter ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are included herewith:
Exhibit No.Description of Exhibit 99.1Press release dated July 30, 2025, issued by CONMED Corporation.
104Cover Page Interactive Data File (embedded within the Inline XBRL Document).
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 30, 2025
CONMED CORPORATION
(Registrant)
By: /s/ Todd W. Garner Name:Todd W. Garner Title:Executive Vice President, Finance & Chief Financial Officer
Latest CONMED Corporation News
CNMD Breaking Stock News: Dive into CNMD Ticker-Specific Updates for Smart Investing
Compare CNMD vs Leading Stocks
See how CNMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CNMD CONMED Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.